Hemagen Diagnostics, Inc.
HMGN · OTC
9/30/2012 | 9/30/2011 | 9/30/2010 | 9/30/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | -0.00 | 0.07 | 0.01 |
| FCF Yield | -96.72% | -84.77% | -27.75% | -8.05% |
| EV / EBITDA | -19.81 | -17.50 | 12.16 | -28.86 |
| Quality | ||||
| ROIC | -29.79% | -23.37% | 21.25% | -13.31% |
| Gross Margin | 39.92% | 38.14% | 45.14% | 38.24% |
| Cash Conversion Ratio | 0.40 | 0.38 | 1.17 | -0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.17% | -1.74% | -6.44% | 6.49% |
| Free Cash Flow Growth | -14.26% | -52.95% | -162.38% | 4.77% |
| Safety | ||||
| Net Debt / EBITDA | -18.11 | -15.87 | 10.00 | -22.52 |
| Interest Coverage | -0.93 | -1.16 | 0.71 | -0.86 |
| Efficiency | ||||
| Inventory Turnover | 1.78 | 2.18 | 2.07 | 1.96 |
| Cash Conversion Cycle | 202.48 | 163.67 | 198.87 | 181.26 |